← Companies
Organization
Yilai Shu
Organization-level profile for a sponsor, institution, collaborator, or mixed-role entity. These profiles are separated from the primary industry company index when appropriate.
Programs
2
linked to organization
Strong Evidence
0
0 status confirmed
Details Checked
2
0 open data checks
Company / Institution Links
1 / 1
industry vs non-industry records
Competitive Density
6
Pipeline Velocity
70
Completion Signal
0
Programs by Stage
Interventional/NA2
Trial / Program Status
Active2
Modality Mix
Gene Therapy1
Small Molecule1
Indication Coverage
Hearing Loss2
Sensorineural Hearing Loss2
Age-Related Hearing Loss1
Genetic Hearing Loss1
OTOF-Related Hearing Loss1
Program Types
Therapeutic2
Population Tags
adult1
age-related1
congenital1
genetic1
older-adult1
pediatric1
pre-lingual1
profound1
sensorineural1
Strong-Evidence Records
0 recordsNo strong-evidence records are linked to this organization yet.
Checked Records With Caveats
2 checked · 0 open checksFudan EH002 OTOF gene therapy study
Details checked
Gene TherapyInterventional/NAActive
Recruiting investigator-led study evaluating intracochlear EH002 gene therapy for congenital deafness caused by OTOF mutations, with dose-escalation cohorts and safety, tolerability, and preliminary efficacy endpoints.
Data checks: institution-led-study, active-recruiting
TJ0113 Capsules by Hangzhou PhecdaMed
Details checked
Small MoleculeInterventional/NAActive
Oral investigational small molecule being evaluated in a randomized placebo-controlled study for age-related hearing loss; public mechanism details were not confirmed in this pass.
Data checks: registry-only-no-company-program-page, phase-not-publicly-normalized